SAT0240 Phase 3 trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE) - Merrill, J; Martin, RS; Shanahan, WR; Scheinberg, M; Kalunian, K; Wofsy, D (Annals of the rheumatic diseases, 2017)
Keywords: Anti-DNA antibodies; Antimalarial agents; Antiphospholipid antibodies; BLyS protein; Cardiolipin; Clinical trials; Complement component C3; Complement component C4; Corticosteroids; Diarrhea; Erythema; Immunoglobulin G; Injection; Lupus; Lymphocytes B; Patients; Phospholipids; Population studies; Prednisone; Proteinuria; Respiratory tract diseases; Response rates; Stockholders; Systemic lupus erythematosus; Urinary tract